Arine Platform
AI-powered medication intelligence platform combining clinical and data science
Platform · Cloud SaaSCompany source
Company profile
About Arine
Arine uses AI to optimize medication therapy management, identifying patients at risk of medication-related problems and recommending personalized interventions.
Company description Arine official website
Primary marketPharmacy & Medication Management
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Arine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- At-risk Provider Organizations
- Commercial plans
- Health Plans
- Medicaid plans
- Medicare plans
- PBMs
- Special Needs Plans
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Recognized by Inc. 5000 as one of America's Fastest-Growing Companies in 2024, ranking 236 overall and 5th in AI. 100% revenue growth in 2023. Expanded to 30+ health plan partnerships. Touched 30+ million lives and produced 40+ million recommendations annually.
Partnerships
Recorded partners
- Blue Shield of California
- Five National Health Plans
- Oklahoma Healthcare Authority
- Priority Health
- SCAN Health Plan
- Seven Blues Plans
- Two National PBMs
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ELEVATE Quality Improvement
Achieve 4-5 Star Ratings across your population for Quality and MTM measures
Platform · Cloud SaaSCompany source
LUMINATE High-Risk Solution
Proactive interventions for patients at higher risk of medication-related problems
Platform · Cloud SaaSCompany source
Medication Therapy Management
Comprehensive medication management solutions for diverse populations
Platform · Cloud SaaSCompany source
RESONATE Prescriber Analytics
Leverage AI algorithms to extend reach through prescribers while reducing cost of care
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Evaluation of the National Accreditation Program for Rectal Cancer and Association with Oncologic Outcomes After Proctectomy.Journal of the American College of Surgeons · May 19, 2026
Pediatricians' approaches to communicating side effects: a national survey.European journal of pediatrics · Mar 3, 2026
A new era of surgical intelligence: Analyzing disruption in general surgery from 2015 to 2021.American journal of surgery · Mar 1, 2026
Return of the Disruption Score: Fetal Surgery in the Spotlight (1975-2021).Journal of pediatric surgery · Jul 1, 2025
Identifying disruptive papers in pharmacy literature that changed clinical practice: 1954-2014.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · Mar 7, 2025
Effects of individualized nurse-led care plans on olaparib treatment duration.The American journal of managed care · Jan 1, 2025
Clinical validation
Clinical-trial records
Online Medical Hypnosis Exercises to Improve Mental Health in Primary School Children and Prevent Future Mental Health IssuesNCT07157358 · Mentioned · RECRUITING
Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT StudyNCT05799053 · Mentioned · COMPLETED
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.NCT06797570 · Mentioned · NOT YET RECRUITING
Management of Eczema by Specific Probiotic StrainsNCT01230190 · Mentioned · WITHDRAWN
Intestinal Microbiota Composition After Antibiotic Treatment in Early LifeNCT02536560 · Mentioned · UNKNOWN
Efficacy of Arnica D1 Ointment After Upper BlepharoplastyNCT01598909 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
>10% Decreased Total Cost of Care
across client populations
40% Reduction in Hospitalizations
across client populations
4-5 Stars Ratings Achieved
CMS quality and MTM measures
15% reduction in cost of care
2020 results
92% adherence to antihypertensives
SCAN Health Plan Medicare population
92% CMR completion rate for MTM
SCAN Health Plan
+3 stars improvement to 5 stars
health plan quality ratings
Blue Shield of California
Achieve higher quality ratings across Part C and D Star measures for CMS
Higher quality ratings achieved
Priority Health
Achieve higher quality ratings across Part C and D Star measures for CMS
Higher quality ratings achieved
Aggregate Client Results
Comprehensive medication management across Medicare, Medicaid, Special Needs, and Commercial populations
>10% decreased total cost of care, 40% reduction in hospitalizations, 4-5 Stars ratings achieved, 15% cost of care reduction, +3 stars improvement to 5 stars
Oklahoma Healthcare Authority
Improve population health while driving cost savings through medication intelligence
Cost savings achieved (specific metrics in case study)
SCAN Health Plan
Deliver high-quality care to Medicare population including medication adherence and MTM completion
92% adherence to antihypertensives, 92% CMR completion rate for MTM, exceeded statin adherence goal in Hispanic population
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Yoona Kim
Co-founder and CEO
Ndinda Domingos, PharmD, BCACP
Clinical Product Pharmacist
Mackey Stewart Long
Vice President of Payer Markets
Stuart Hammond
Vice President, Sales
Joshua Sopeth
Vice President, Client Success
Eunice Kim
Vice President of Clinical Product
Sean Handel
Chief Product Officer
06 · Company updates
Updates from Arine
Recent articles published on Arine's official website.
AI-Driven Medication Use Quality as a Vehicle for Value-Based Care
Read on ArineArine Earns Third Consecutive Inc. 5000 Recognition as Demand for Medication AI Accelerates
Read on ArineAfter Clover v. HHS: Why Medication Optimization Still Matters for Health Plan
Read on ArineThe Rising Burden of Polypharmacy: A Systemic Challenge Requiring Systemic Solutions
Read on ArineMedications: The Missing Link in Value-Based Care
Read on Arine07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pharmacy & Medication Management
Companies using AI for medication optimization, pharmacy automation, drug pricing and access, medication adherence, polypharmacy management, or pharmacy workflow optimization. Includes platforms that help patients access affordable medications, tools that reduce medication errors, and AI systems that optimize drug regimens for complex patients.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.